NEWS: 公告在東京證券交易所JASDAQ標準市場新上市

表紙
市場調查報告書

阿茲海默症藥物市場:全球產業趨勢,佔有率,規模,成長,機會,預測(2020∼2025年)

Alzheimer's Drugs Market: Global Industry Trends, Share, Size, Growth, Opportunity and Forecast 2020-2025

出版商 IMARC Services Private Limited 商品編碼 975962
出版日期 內容資訊 英文 151 Pages
商品交期: 2-3個工作天內
價格
阿茲海默症藥物市場:全球產業趨勢,佔有率,規模,成長,機會,預測(2020∼2025年) Alzheimer's Drugs Market: Global Industry Trends, Share, Size, Growth, Opportunity and Forecast 2020-2025
出版日期: 2020年12月05日內容資訊: 英文 151 Pages
簡介

全球阿茲海默症藥物的市場規模,從2014年到2019年以約8%的年複合成長率擴大。久坐的生活方式,不健康的飲食模式及抽煙,提高糖尿病、肥胖、心臟病及高血壓(BP)、阿茲海默症發病的可能性。這些疾病盛行率和在大眾之間選擇的生活方式,加上老年人口增加,成為促進市場成長的重要要素。除此之外,各種用於治療阿茲海默症的藥物,例如Aducanumab,Solanezumab和胰島素,目前正在後期臨床試驗中。這些藥物的開發有望在未來幾年內推動市場成長。未來,全球阿茲海默症藥物市場預計今後五年繼續緩慢成長。

本報告提供阿茲海默症藥物市場相關調查,市場概要,以及各類藥物,各流通管道,各地區的趨勢,及加入此市場的主要企業簡介等資訊。

目錄

第1章 序文

第2章 範圍與調查手法

第3章 摘要整理

第4章 簡介

第5章 全球阿茲海默症藥物市場

  • 市場概要
  • 市場效能
  • COVID-19的影響

第6章 市場區隔,各類藥物

  • Donepezil
  • Galantamine
  • Rivastigmine
  • Memantine
  • 其他

第7章 市場區隔,各流通管道

  • 醫院藥局
  • 零售藥局
  • 網路商店
  • 其他

第8章 市場區隔,各地區

  • 北美
    • 美國
    • 加拿大
  • 亞太地區
    • 中國
    • 日本
    • 印度
    • 韓國
    • 澳洲
    • 印尼
    • 其他
  • 歐洲
    • 德國
    • 法國
    • 英國
    • 義大利
    • 西班牙
    • 俄羅斯
    • 其他
  • 南美
    • 巴西
    • 墨西哥
    • 其他
  • 中東和非洲
    • 市場區隔,各國

第9章 SWOT分析

第10章 價值鏈分析

第11章 波特五力分析

第12章 價格分析

第13章 競爭情形

  • 市場結構
  • 主要參與者
  • 主要參與者的簡介
    • Abbvie Inc.
    • AstraZeneca PLC
    • Biogen Inc.
    • Daiichi Sankyo Company Limited
    • Eisai Co. Ltd.
    • Eli Lilly and Company
    • H. Lundbeck A/S
    • F. Hoffmann-La Roche AG
    • Merck & Co. Inc.
    • Novartis AG
    • Ono Pharmaceutical Co. Ltd.
    • Pfizer Inc.
    • Teva Pharmaceutical Industries Limited
目錄
Product Code: SR1019O53_Report

The global alzeimer's drugs market grew at a CAGR of around 8% during 2014-2019. Alzheimer's is a disease characterized by the degeneration of nerve cells in several areas of the brain. It causes loss of cognitive function, such as memory, language, thinking and behavior. The common symptoms of Alzheimer's include depression, memory impairment, loss of inhibitions, and problems with thinking and reasoning. It is usually diagnosed by performing physical exams, blood tests, brain imaging, and mental status and neuropsychological testing. According to the results, doctors prescribe different medications to alleviate symptoms. Alzheimer's drugs influence the functions of neurotransmitters, the chemicals involved in carrying messages between nerve cells in the brain.

Diabetes, obesity, heart diseases and high blood pressure (BP), in confluence with sedentary lifestyles, unhealthy dietary patterns and smoking, are some of the factors known to increase the chances of developing Alzheimer's disease. An increase in the prevalence of these ailments and lifestyle choices among the masses, coupled with the rising geriatric population, represents one of the key factors driving the market growth. Furthermore, the leading pharmaceutical companies are focusing on the development of drugs that prevent the disease and provide long-lasting improvements in cognitive functions. The market growth is further supported by the expansion of telehealth services and the growing traction of online pharmacies. These platforms have enabled disease diagnosis and drug delivery in remote regions. Apart from this, various Alzheimer's drugs are presently under late-stage clinical trials, including Aducanumab, Solanezumab and Insulin. The development of these drugs is anticipated to propel the market growth in the coming years. Looking forward, IMARC Group expects the global alzeimer's drugs market to continue its moderate growth during the next five years.

Key Market Segmentation:

  • IMARC Group provides an analysis of the key trends in each sub-segment of the global alzeimer's drugs market report, along with forecasts for growth at the global, regional and country level from 2020-2025. Our report has categorized the market based on region, drug class and distribution channel.

Breakup by Drug Class:

  • Donepezil
  • Galantamine
  • Rivastigmine
  • Memantine
  • Others

Breakup by Distribution Channel:

  • Hospital Pharmacy
  • Retail Pharmacy
  • Online Stores
  • Others

Breakup by Region:

  • North America
  • United States
  • Canada
  • Asia Pacific
  • China
  • Japan
  • India
  • South Korea
  • Australia
  • Indonesia
  • Others
  • Europe
  • Germany
  • France
  • United Kingdom
  • Italy
  • Spain
  • Russia
  • Others
  • Latin America
  • Brazil
  • Mexico
  • Others
  • Middle East and Africa

Competitive Landscape:

  • The report has also analysed the competitive landscape of the market with some of the key players being Abbvie Inc., AstraZeneca PLC, Biogen Inc., Daiichi Sankyo Company Limited, Daiichi Sankyo Company Limited, Eisai Co. Ltd., Eli Lilly and Company, H. Lundbeck A/S, F. Hoffmann-La Roche AG, Merck & Co. Inc., Novartis AG, Ono Pharmaceutical Co. Ltd., Pfizer Inc and Teva Pharmaceutical Industries Limited.

Key Questions Answered in This Report:

  • How has the global alzeimer's drugs market performed so far and how will it perform in the coming years?
  • What has been the impact of COVID-19 on the global alzeimer's drugs market?
  • What are the key regional markets?
  • What is the breakup of the market based on the drug class?
  • What is the breakup of the market based on the distribution channel?
  • What are the various stages in the value chain of the industry?
  • What are the key driving factors and challenges in the industry?
  • What is the structure of the global alzeimer's drugs market and who are the key players?
  • What is the degree of competition in the industry?

Table of Contents

1 Preface

2 Scope and Methodology

  • 2.1 Objectives of the Study
  • 2.2 Stakeholders
  • 2.3 Data Sources
    • 2.3.1 Primary Sources
    • 2.3.2 Secondary Sources
  • 2.4 Market Estimation
    • 2.4.1 Bottom-Up Approach
    • 2.4.2 Top-Down Approach
  • 2.5 Forecasting Methodology

3 Executive Summary

4 Introduction

  • 4.1 Overview
  • 4.2 Key Industry Trends

5 Global Alzeimer's Drugs Market

  • 5.1 Market Overview
  • 5.2 Market Performance
  • 5.3 Impact of COVID-19
  • 5.4 Market Forecast

6 Market Breakup by Drug Class

  • 6.1 Donepezil
    • 6.1.1 Market Trends
    • 6.1.2 Market Forecast
  • 6.2 Galantamine
    • 6.2.1 Market Trends
    • 6.2.2 Market Forecast
  • 6.3 Rivastigmine
    • 6.3.1 Market Trends
    • 6.3.2 Market Forecast
  • 6.4 Memantine
    • 6.4.1 Market Trends
    • 6.4.2 Market Forecast
  • 6.5 Others
    • 6.5.1 Market Trends
    • 6.5.2 Market Forecast

7 Market Breakup by Distribution Channel

  • 7.1 Hospital Pharmacy
    • 7.1.1 Market Trends
    • 7.1.2 Market Forecast
  • 7.2 Retail Pharmacy
    • 7.2.1 Market Trends
    • 7.2.2 Market Forecast
  • 7.3 Online Stores
    • 7.3.1 Market Trends
    • 7.3.2 Market Forecast
  • 7.4 Others
    • 7.4.1 Market Trends
    • 7.4.2 Market Forecast

8 Market Breakup by Region

  • 8.1 North America
    • 8.1.1 United States
      • 8.1.1.1 Market Trends
      • 8.1.1.2 Market Forecast
    • 8.1.2 Canada
      • 8.1.2.1 Market Trends
      • 8.1.2.2 Market Forecast
  • 8.2 Asia Pacific
    • 8.2.1 China
      • 8.2.1.1 Market Trends
      • 8.2.1.2 Market Forecast
    • 8.2.2 Japan
      • 8.2.2.1 Market Trends
      • 8.2.2.2 Market Forecast
    • 8.2.3 India
      • 8.2.3.1 Market Trends
      • 8.2.3.2 Market Forecast
    • 8.2.4 South Korea
      • 8.2.4.1 Market Trends
      • 8.2.4.2 Market Forecast
    • 8.2.5 Australia
      • 8.2.5.1 Market Trends
      • 8.2.5.2 Market Forecast
    • 8.2.6 Indonesia
      • 8.2.6.1 Market Trends
      • 8.2.6.2 Market Forecast
    • 8.2.7 Others
      • 8.2.7.1 Market Trends
      • 8.2.7.2 Market Forecast
  • 8.3 Europe
    • 8.3.1 Germany
      • 8.3.1.1 Market Trends
      • 8.3.1.2 Market Forecast
    • 8.3.2 France
      • 8.3.2.1 Market Trends
      • 8.3.2.2 Market Forecast
    • 8.3.3 United Kingdom
      • 8.3.3.1 Market Trends
      • 8.3.3.2 Market Forecast
    • 8.3.4 Italy
      • 8.3.4.1 Market Trends
      • 8.3.4.2 Market Forecast
    • 8.3.5 Spain
      • 8.3.5.1 Market Trends
      • 8.3.5.2 Market Forecast
    • 8.3.6 Russia
      • 8.3.6.1 Market Trends
      • 8.3.6.2 Market Forecast
    • 8.3.7 Others
      • 8.3.7.1 Market Trends
      • 8.3.7.2 Market Forecast
  • 8.4 Latin America
    • 8.4.1 Brazil
      • 8.4.1.1 Market Trends
      • 8.4.1.2 Market Forecast
    • 8.4.2 Mexico
      • 8.4.2.1 Market Trends
      • 8.4.2.2 Market Forecast
    • 8.4.3 Others
      • 8.4.3.1 Market Trends
      • 8.4.3.2 Market Forecast
  • 8.5 Middle East and Africa
    • 8.5.1 Market Trends
    • 8.5.2 Market Breakup by Country
    • 8.5.3 Market Forecast

9 SWOT Analysis

  • 9.1 Overview
  • 9.2 Strengths
  • 9.3 Weaknesses
  • 9.4 Opportunities
  • 9.5 Threats

10 Value Chain Analysis

11 Porters Five Forces Analysis

  • 11.1 Overview
  • 11.2 Bargaining Power of Buyers
  • 11.3 Bargaining Power of Suppliers
  • 11.4 Degree of Competition
  • 11.5 Threat of New Entrants
  • 11.6 Threat of Substitutes

12 Price Analysis

13 Competitive Landscape

  • 13.1 Market Structure
  • 13.2 Key Players
  • 13.3 Profiles of Key Players
    • 13.3.1 Abbvie Inc.
      • 13.3.1.1 Company Overview
      • 13.3.1.2 Product Portfolio
      • 13.3.1.3 Financials
      • 13.3.1.4 SWOT Analysis
    • 13.3.2 AstraZeneca PLC
      • 13.3.2.1 Company Overview
      • 13.3.2.2 Product Portfolio
      • 13.3.2.3 Financials
      • 13.3.2.4 SWOT Analysis
    • 13.3.3 Biogen Inc.
      • 13.3.3.1 Company Overview
      • 13.3.3.2 Product Portfolio
      • 13.3.3.3 Financials
      • 13.3.3.4 SWOT Analysis
    • 13.3.4 Daiichi Sankyo Company Limited
      • 13.3.4.1 Company Overview
      • 13.3.4.2 Product Portfolio
      • 13.3.4.3 Financials
      • 13.3.4.4 SWOT Analysis
    • 13.3.5 Eisai Co. Ltd.
      • 13.3.5.1 Company Overview
      • 13.3.5.2 Product Portfolio
      • 13.3.5.3 Financials
      • 13.3.5.4 SWOT Analysis
    • 13.3.6 Eli Lilly and Company
      • 13.3.6.1 Company Overview
      • 13.3.6.2 Product Portfolio
      • 13.3.6.3 Financials
      • 13.3.6.4 SWOT Analysis
    • 13.3.7 H. Lundbeck A/S
      • 13.3.7.1 Company Overview
      • 13.3.7.2 Product Portfolio
      • 13.3.7.3 Financials
      • 13.3.7.4 SWOT Analysis
    • 13.3.8 F. Hoffmann-La Roche AG
      • 13.3.8.1 Company Overview
      • 13.3.8.2 Product Portfolio
      • 13.3.8.3 SWOT Analysis
    • 13.3.9 Merck & Co. Inc.
      • 13.3.9.1 Company Overview
      • 13.3.9.2 Product Portfolio
      • 13.3.9.3 Financials
      • 13.3.9.4 SWOT Analysis
    • 13.3.10 Novartis AG
      • 13.3.10.1 Company Overview
      • 13.3.10.2 Product Portfolio
      • 13.3.10.3 Financials
      • 13.3.10.4 SWOT Analysis
    • 13.3.11 Ono Pharmaceutical Co. Ltd.
      • 13.3.11.1 Company Overview
      • 13.3.11.2 Product Portfolio
      • 13.3.11.3 Financials
      • 13.3.11.4 SWOT Analysis
    • 13.3.12 Pfizer Inc.
      • 13.3.12.1 Company Overview
      • 13.3.12.2 Product Portfolio
      • 13.3.12.3 Financials
      • 13.3.12.4 SWOT Analysis
    • 13.3.13 Teva Pharmaceutical Industries Limited
      • 13.3.13.1 Company Overview
      • 13.3.13.2 Product Portfolio
      • 13.3.13.3 Financials
      • 13.3.13.4 SWOT Analysis

List of Figures

  • Figure 1: Global: Alzeimer's Drugs Market: Major Drivers and Challenges
  • Figure 2: Global: Alzeimer's Drugs Market: Sales Value (in Billion US$), 2014-2019
  • Figure 3: Global: Alzeimer's Drugs Market: Breakup by Drug Class (in %), 2019
  • Figure 4: Global: Alzeimer's Drugs Market: Breakup by Distribution Channel (in %), 2019
  • Figure 5: Global: Alzeimer's Drugs Market: Breakup by Region (in %), 2019
  • Figure 6: Global: Alzeimer's Drugs Market Forecast: Sales Value (in Billion US$), 2020-2025
  • Figure 7: Global: Alzeimer's Drugs (Donepezil) Market: Sales Value (in Million US$), 2014 & 2019
  • Figure 8: Global: Alzeimer's Drugs (Donepezil) Market Forecast: Sales Value (in Million US$), 2020-2025
  • Figure 9: Global: Alzeimer's Drugs (Galantamine) Market: Sales Value (in Million US$), 2014 & 2019
  • Figure 10: Global: Alzeimer's Drugs (Galantamine) Market Forecast: Sales Value (in Million US$), 2020-2025
  • Figure 11: Global: Alzeimer's Drugs (Rivastigmine) Market: Sales Value (in Million US$), 2014 & 2019
  • Figure 12: Global: Alzeimer's Drugs (Rivastigmine) Market Forecast: Sales Value (in Million US$), 2020-2025
  • Figure 13: Global: Alzeimer's Drugs (Memantine) Market: Sales Value (in Million US$), 2014 & 2019
  • Figure 14: Global: Alzeimer's Drugs (Memantine) Market Forecast: Sales Value (in Million US$), 2020-2025
  • Figure 15: Global: Alzeimer's Drugs (Other Drug Classes) Market: Sales Value (in Million US$), 2014 & 2019
  • Figure 16: Global: Alzeimer's Drugs (Other Drug Classes) Market Forecast: Sales Value (in Million US$), 2020-2025
  • Figure 17: Global: Alzeimer's Drugs (Hospital Pharmacy) Market: Sales Value (in Million US$), 2014 & 2019
  • Figure 18: Global: Alzeimer's Drugs (Hospital Pharmacy) Market Forecast: Sales Value (in Million US$), 2020-2025
  • Figure 19: Global: Alzeimer's Drugs (Retail Pharmacy) Market: Sales Value (in Million US$), 2014 & 2019
  • Figure 20: Global: Alzeimer's Drugs (Retail Pharmacy) Market Forecast: Sales Value (in Million US$), 2020-2025
  • Figure 21: Global: Alzeimer's Drugs (Online Stores) Market: Sales Value (in Million US$), 2014 & 2019
  • Figure 22: Global: Alzeimer's Drugs (Online Stores) Market Forecast: Sales Value (in Million US$), 2020-2025
  • Figure 23: Global: Alzeimer's Drugs (Other Distribution Channels) Market: Sales Value (in Million US$), 2014 & 2019
  • Figure 24: Global: Alzeimer's Drugs (Other Distribution Channels) Market Forecast: Sales Value (in Million US$), 2020-2025
  • Figure 25: North America: Alzeimer's Drugs Market: Sales Value (in Million US$), 2014 & 2019
  • Figure 26: North America: Alzeimer's Drugs Market Forecast: Sales Value (in Million US$), 2020-2025
  • Figure 27: United States: Alzeimer's Drugs Market: Sales Value (in Million US$), 2014 & 2019
  • Figure 28: United States: Alzeimer's Drugs Market Forecast: Sales Value (in Million US$), 2020-2025
  • Figure 29: Canada: Alzeimer's Drugs Market: Sales Value (in Million US$), 2014 & 2019
  • Figure 30: Canada: Alzeimer's Drugs Market Forecast: Sales Value (in Million US$), 2020-2025
  • Figure 31: Asia Pacific: Alzeimer's Drugs Market: Sales Value (in Million US$), 2014 & 2019
  • Figure 32: Asia Pacific: Alzeimer's Drugs Market Forecast: Sales Value (in Million US$), 2020-2025
  • Figure 33: China: Alzeimer's Drugs Market: Sales Value (in Million US$), 2014 & 2019
  • Figure 34: China: Alzeimer's Drugs Market Forecast: Sales Value (in Million US$), 2020-2025
  • Figure 35: Japan: Alzeimer's Drugs Market: Sales Value (in Million US$), 2014 & 2019
  • Figure 36: Japan: Alzeimer's Drugs Market Forecast: Sales Value (in Million US$), 2020-2025
  • Figure 37: India: Alzeimer's Drugs Market: Sales Value (in Million US$), 2014 & 2019
  • Figure 38: India: Alzeimer's Drugs Market Forecast: Sales Value (in Million US$), 2020-2025
  • Figure 39: South Korea: Alzeimer's Drugs Market: Sales Value (in Million US$), 2014 & 2019
  • Figure 40: South Korea: Alzeimer's Drugs Market Forecast: Sales Value (in Million US$), 2020-2025
  • Figure 41: Australia: Alzeimer's Drugs Market: Sales Value (in Million US$), 2014 & 2019
  • Figure 42: Australia: Alzeimer's Drugs Market Forecast: Sales Value (in Million US$), 2020-2025
  • Figure 43: Indonesia: Alzeimer's Drugs Market: Sales Value (in Million US$), 2014 & 2019
  • Figure 44: Indonesia: Alzeimer's Drugs Market Forecast: Sales Value (in Million US$), 2020-2025
  • Figure 45: Others: Alzeimer's Drugs Market: Sales Value (in Million US$), 2014 & 2019
  • Figure 46: Others: Alzeimer's Drugs Market Forecast: Sales Value (in Million US$), 2020-2025
  • Figure 47: Europe: Alzeimer's Drugs Market: Sales Value (in Million US$), 2014 & 2019
  • Figure 48: Europe: Alzeimer's Drugs Market Forecast: Sales Value (in Million US$), 2020-2025
  • Figure 49: Germany: Alzeimer's Drugs Market: Sales Value (in Million US$), 2014 & 2019
  • Figure 50: Germany: Alzeimer's Drugs Market Forecast: Sales Value (in Million US$), 2020-2025
  • Figure 51: France: Alzeimer's Drugs Market: Sales Value (in Million US$), 2014 & 2019
  • Figure 52: France: Alzeimer's Drugs Market Forecast: Sales Value (in Million US$), 2020-2025
  • Figure 53: United Kingdom: Alzeimer's Drugs Market: Sales Value (in Million US$), 2014 & 2019
  • Figure 54: United Kingdom: Alzeimer's Drugs Market Forecast: Sales Value (in Million US$), 2020-2025
  • Figure 55: Italy: Alzeimer's Drugs Market: Sales Value (in Million US$), 2014 & 2019
  • Figure 56: Italy: Alzeimer's Drugs Market Forecast: Sales Value (in Million US$), 2020-2025
  • Figure 57: Spain: Alzeimer's Drugs Market: Sales Value (in Million US$), 2014 & 2019
  • Figure 58: Spain: Alzeimer's Drugs Market Forecast: Sales Value (in Million US$), 2020-2025
  • Figure 59: Russia: Alzeimer's Drugs Market: Sales Value (in Million US$), 2014 & 2019
  • Figure 60: Russia: Alzeimer's Drugs Market Forecast: Sales Value (in Million US$), 2020-2025
  • Figure 61: Others: Alzeimer's Drugs Market: Sales Value (in Million US$), 2014 & 2019
  • Figure 62: Others: Alzeimer's Drugs Market Forecast: Sales Value (in Million US$), 2020-2025
  • Figure 63: Latin America: Alzeimer's Drugs Market: Sales Value (in Million US$), 2014 & 2019
  • Figure 64: Latin America: Alzeimer's Drugs Market Forecast: Sales Value (in Million US$), 2020-2025
  • Figure 65: Brazil: Alzeimer's Drugs Market: Sales Value (in Million US$), 2014 & 2019
  • Figure 66: Brazil: Alzeimer's Drugs Market Forecast: Sales Value (in Million US$), 2020-2025
  • Figure 67: Mexico: Alzeimer's Drugs Market: Sales Value (in Million US$), 2014 & 2019
  • Figure 68: Mexico: Alzeimer's Drugs Market Forecast: Sales Value (in Million US$), 2020-2025
  • Figure 69: Others: Alzeimer's Drugs Market: Sales Value (in Million US$), 2014 & 2019
  • Figure 70: Others: Alzeimer's Drugs Market Forecast: Sales Value (in Million US$), 2020-2025
  • Figure 71: Middle East and Africa: Alzeimer's Drugs Market: Sales Value (in Million US$), 2014 & 2019
  • Figure 72: Middle East and Africa: Alzeimer's Drugs Market Forecast: Sales Value (in Million US$), 2020-2025
  • Figure 73: Global: Alzeimer's Drugs Industry: SWOT Analysis
  • Figure 74: Global: Alzeimer's Drugs Industry: Value Chain Analysis
  • Figure 75: Global: Alzeimer's Drugs Industry: Porter's Five Forces Analysis

List of Tables

  • Table 1: Global: Alzeimer's Drugs Market: Key Industry Highlights, 2019 and 2025
  • Table 2: Global: Alzeimer's Drugs Market Forecast: Breakup by Drug Class (in Million US$), 2020-2025
  • Table 3: Global: Alzeimer's Drugs Market Forecast: Breakup by Distribution Channel (in Million US$), 2020-2025
  • Table 4: Global: Alzeimer's Drugs Market Forecast: Breakup by Region (in Million US$), 2020-2025
  • Table 5: Global: Alzeimer's Drugs Market Structure
  • Table 6: Global: Alzeimer's Drugs Market: Key Players